Scarica l'app Stockscreener
1.3375
6.10%
0.0775
Inmune Bio Inc Borsa (INMB) Ultime notizie
INmune Bio Advances XPro Toward Registrational Alzheimer’s Study - TipRanks
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar - The Manila Times
INmune Bio Inc. Announces Webinar on XPro1595 Registrational Pathway for Early Alzheimer's Disease Treatment - Quiver Quantitative
Alzheimer’s therapy XPro1595 nears key trial as INmune Bio details Phase 3 path - Stock Titan
Levels Update: Is INmune Bio Inc stock undervalued right nowMarket Sentiment Review & Daily Stock Trend Reports - baoquankhu1.vn
INmune Bio to host webinar on RDEB treatment data - Investing.com Australia
INmune Bio to Present New CORDStrom Phase III Data - TipRanks
INmune Bio to Host Feb. 26 Webinar Presenting MissionEB Phase III CORDStrom Data - TradingView
INmune Bio to host webinar on RDEB treatment data By Investing.com - Investing.com Nigeria
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB - The Manila Times
INmune Bio Inc. to Host Webinar on CORDStrom Treatment for Recessive Dystrophic Epidermolysis Bullosa, Highlighting New Clinical Data and Insights from MissionEB Study - Quiver Quantitative
New trial data on systemic treatment for a painful skin disease - Stock Titan
INMB stock rises pre-market – what did the FDA say about its Alzheimer’s trial? - MSN
Aug Action: What are INmune Bio Incs earnings expectations2025 Top Gainers & Expert Curated Trade Ideas - baoquankhu1.vn
INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits
Is INmune Bio Inc. stock a buy for dividend growthPortfolio Growth Summary & Technical Analysis for Trade Confirmation - mfd.ru
INmune Bio Advances CORDStrom Toward Rare Disease Commercialization - TipRanks
Inmune Bio Inc Advances CORDStrom and XPro1595 Regulatory Pathways - TradingView
Inmune Bio plans to seek approval of RDEB treatment in UK, US, and EU in 2026 - Epidermolysis Bullosa News
Inmune Bio announces FDA alignment on integrated Phase 2B/3 registration pathway for Xpro1595 in early Alzheimer's disease - marketscreener.com
Inmune Bio announces FDA alignment on integrated phase 2B/3 registration pathway for Xpro1595 in early Alzheimer's disease - marketscreener.com
INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial? - Asianet Newsable
INmune Bio Gains FDA Alignment On Phase 2b/3 Trial Design For Alzheimer's Drug XPro1595 - Nasdaq
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease - The Manila Times
Will INmune Bio Inc. benefit from geopolitical trends2025 Market Outlook & Daily Growth Stock Investment Tips - mfd.ru
Is INmune Bio Inc. stock a value trapRate Hike & Safe Entry Momentum Tips - mfd.ru
INmune Bio submits pre-submission package for CORDStrom with MHRA - Yahoo Finance
INmune Bio, Inc. (NASDAQ:INMB) Given Average Rating of “Reduce” by Brokerages - Defense World
Inmune Bio Inc Submitted Pre-Submission Package For Cordstrom With Uk's Mhra - TradingView
Inmune Bio Advances Cordstrom™ Towards Uk Marketing Authorization In Rdeb - TradingView
INmune Bio (INMB) Advances with Regulatory Submission for CORDSt - GuruFocus
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB - The Manila Times
Rare 'butterfly skin' disease therapy takes key step toward UK review - Stock Titan
Death Cross: Whats the profit margin of INmune Bio IncJuly 2025 Gainers & Verified Chart Pattern Signals - baoquankhu1.vn
Smart Money: Will INmune Bio Inc benefit from geopolitical trendsJuly 2025 Trends & Consistent Profit Trading Strategies - baoquankhu1.vn
Retail Surge: What is the earnings history of INmune Bio Inc2025 Valuation Update & Fast Gaining Stock Reports - baoquankhu1.vn
Aug Movers: Will INmune Bio Inc benefit from geopolitical trendsInsider Buying & Expert Approved Momentum Ideas - baoquankhu1.vn
INmune Bio: Undervalued Pipeline with 2026 Clinical and Regulatory Catalysts Driving Buy Rating - TipRanks
INmune Bio outlines 2025 progress on Alzheimer’s and RDEB therapies By Investing.com - Investing.com Australia
New Highs: Can ProShares Trust ProShares UltraShort SmallCap600 expand into new marketsDollar Strength & Reliable Intraday Trade Plans - baoquankhu1.vn
INmune Bio outlines 2026 regulatory path in shareholder letter - TipRanks
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - TradingView
INmune Bio (INMB) Reflects on Key Progress and Financial Stabili - GuruFocus
INmune Bio (INMB) Reflects on Key Progress and Financial Stability in 2025 - GuruFocus
INmune Bio outlines 2025 progress on Alzheimer’s and RDEB therapies - Investing.com
INmune Bio, Inc. Provides Investor Update on 2025 Progress and Future Regulatory Plans - Quiver Quantitative
Sell Signal: Will Reading International Inc benefit from geopolitical trends2025 Trading Recap & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Aug Rallies: What is the earnings history of INmune Bio IncMarket Performance Report & Daily Technical Forecast Reports - baoquankhu1.vn
Is INmune Bio Inc. trading at a discountDay Trade & Reliable Price Breakout Alerts - bollywoodhelpline.com
Take Profit: Is Varex Imaging Corporation still a buy after recent gains - baoquankhu1.vn
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial - MSN
1.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):